Seeking Alpha

United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the...

United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the company's new drug application for treprostinil, an oral treatment for high blood pressure. The agency is uncertain whether another study would help change its mind, but said that if UTHR does decide on a further trial, it should consider a fixed dose design and more frequent dosing. (PR)
Comments (1)
  • alph124
    , contributor
    Comments (30) | Send Message
     
    Unusual to hear a CEO talk about how great the business on a conference call only days before an earnings release.
    24 Oct 2012, 08:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector